Navigation Links
Transcriptase in Biological Technology

Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference

... novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human ... of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients" ... is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully ...

Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections

... data on the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds, including ... RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of ... candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study ...

Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting

... Presentation Title: RDEA806, a Novel HIV Non-Nucleoside Reverse transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients ... most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for ...

Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology

... RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 ... most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. ...

Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences

... data will be presented on its second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), at the 21st International Conference on Antiviral ... Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. ...

FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy

... INTELENCE (etravirine) tablets -- the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced ... that partially or completely stop the NNRTI from binding to the reverse transcriptase enzyme, causing the drug to lose effectiveness. As with other HIV ...

Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results

... clinical studies of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV, in August of 2007; -- Presentation of four ... year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase ...

A New Era in the Application of Lab-on-a-Chip to Rapid Point-of-Care Diagnosis

... capture (NASBA-EOC). The VDS technology has an advantage of not requiring the use of specialized equipment; VetDetect utilizes real-time reverse transcriptase polymerase chain reaction (RT-PCR) and VetScreen employs the conventional gel-based RT-PCR technique. All three platforms are highly sensitive and ...

Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)

... Tablets are the generic version of Gilead Sciences Inc.'s Truvada(R) Tablets. Truvada(R) is a second-line anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI or "nuke") family and is used in combination with other medications to control HIV infection. Patients often use second-line ...

Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results

... Business Highlights Idenix successfully completed a phase I/II proof-of-concept study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus (HIV) in September 2008. In February 2009, the company announced that it had ...

Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results

... approximately $60.1 million. 2008 Year-to-Date Business Highlights -- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving ...

Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission

... cells, preventing infection. Finally, the third and most potent activity of the product will prevent the critical action of the virus-encoded reverse transcriptase inside the cell. Key features of the development program include the formulation of the product for delivery as gels or intravaginal rings, ...

Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results

... 2008 Year-to-Date Business Highlights -- Idenix has reported positive data from an ongoing phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of ...

Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout

... in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our ...

Craig Johnson Joins Ardea Biosciences' Board of Directors

... in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, ...

Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008

... in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment ...

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

... in the first quarter of 2008 from $120 million in the same period in 2007. -- Sales of the SUSTIVA(R) Franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV, increased 21% to $273 million in the first quarter of 2008 from $226 million in the same period in 2007. ...

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

... "A Novel NNRTI Class with Potent Anti-HIV Activity against NNRTI-Resistant Viruses." About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 may ...

Ardea to Present at Cowen and Company's 28th Annual Health Care Conference

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts

... across its virology portfolio, including the phase III program for its lead compound, apricitabine (ATC), an anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI) class. ATC has successfully completed the 48 week dosing of its Phase 2b trial and the Phase 3 program has been initiated. Avexa ...

Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of ...

Ardea Biosciences Establishes Scientific Advisory Board for HIV Program

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of ...

Ardea Biosciences Announces $40 Million Private Placement

... planned for the first half of 2008. Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a ...

Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference

... planned for the first half of 2008. Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a ...

New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties

... The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor ...

Ardea Biosciences Announces Changes to Research Management

... The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor ...

Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs

... on what we believe is most critical to our future success -- building and advancing our pipeline." Idenix currently has a non-nucleoside reverse transcriptase inhibitor (NNRTI), IDX899, for the treatment of HIV-1 that is being evaluated in phase I/II clinical testing. The company also has a comprehensive ...

Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.

... on three or more compounds this year. These compounds include RDEA806 and lead compounds from our 900 series, which are non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV, and RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and ...

RNA Amplification Just Got Better: MessageAmp II

... , an M-MLV reverse transcriptase specifically engineered to ... Figure 1. ArrayScript Reverse transcriptase Synthesizes Intact cDNA Products as ... Figure 2. ArrayScript Reverse transcriptase Produces up to Twice the aRNA Yield in MessageAmp ...

ArrayScript RT: Maximize Yields of Full-length cDNA

... have engineered a mutant form of M-MLV reverse transcriptase to improve production of full-length ... Figure 1. ArrayScript Reverse transcriptase Synthesizes Intact cDNA Products as ... Figure 2. ArrayScript Reverse transcriptase Produces up to Twice the cRNA Yield in ...

Use of Transcriptor Reverse Transcriptase in Microarray Analysis

... intensities shows that the Transcriptor Reverse transcriptase produced a major shift in the signal distribution ... that target labelling with Transcriptor Reverse transcriptase is highly reproducible and produces fewer outlier ... properties of Transcriptor Reverse transcriptase suggest that it will produce a labelled target ...

Increase the Power and Sensitivity for Your cDNA Synthesis with the New Transcriptor Reverse Transcriptase

... Transcriptor Reverse transcriptase is a new recombinant reverse transcriptase (RT) expressed in E. coli. The enzyme has ... Transcriptor Reverse transcriptase has a broad dynamic detection range of 12 1.2 x ...

Transcriptor Reverse Transcriptase

... with the new Transcriptor Reverse transcriptase With the new ... RNA Transcriptor Reverse transcriptase is the product of choice to transcribe RNA ... inserts Transcriptor Reverse transcriptase will allow you to Get ...

RT-PCR procedures

... In the first step, reverse transcriptase produces first-strand cDNA in the ... the right combination of reverse transcriptase and thermostable DNA polymerase, two-step ... Finally, the thermoactive reverse transcriptase used in this procedure allow a high RT ...
Other Contents
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
(Date:11/4/2014)... A newly published research study examining only marketing ... of fast food restaurants has found that the ... disproportionately exposed to such marketing tactics. , Authored ... her colleagues, the study is the first to ... interior and exterior of fast food restaurants and ...
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
(Date:11/23/2014)... “BlackVue” was featured on NewsWatch as ... features the latest and coolest technology products available to ... NewsWatch, conducted the product review and shared with viewers ... in the car camera industry. , The need for ... hard to find the one that’s right per consumer, ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Wright & ... behalf of Ohio and West Virginia residents who allege ... health disorders due to drinking C8 contaminated water ... Parkersburg, West Virginia. According to the C8 complaints, the ... either worked or lived in at least one of ...
(Date:11/22/2014)... 23, 2014 Every year AlignLife clinics ... AlignLife experience rapid growth in the Greenville, SC area ... opportunity. AlignLife of Simpsonville will be partnering ... their first annual Toy Drive. These six offices came ... support with this year's toy drive. With so many ...
(Date:11/22/2014)... 23, 2014 PrettyTailor , an ... a new big promotion. Customers can buy new dresses ... customers can visit its website. , As a matter ... occasion dresses. It mainly provides four types of wedding ... and flower girl dresses. It also provides a variety ...
(Date:11/22/2014)... November 23, 2014 Recently, Locks-Magnetic.com ... introduced a new promotion of mag locks for glass ... an attracting discount on these fresh products. Customers can ... locks for glass doors are in excellent performance. Customers ... the website as soon as possible. They also ...
Breaking Medicine News(10 mins):Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2
Other TagsOther Tags